Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPAX-1 study of 131I-IPA with second-line radiotherapy in recurrent glioblastoma
2018-002262-39Phase 2Completed
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Jul 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iodine I 131 IPA in glioblastoma (GBM), sponsored by Telix Pharmaceuticals Limited. Primary endpoint: Safety and tolerability. Started Jul 2018; status: completed.
02
Drugs
Iodine I 131 IPA
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2018-002262-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002262-39.